Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00910247 · ClinicalTrials.gov registry record · Phase 3
Eslicarbazepine Acetate Monotherapy Long Term Study
A Phase 3 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 274
- Enrollment target
NCT00910247 is a Phase 3 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 274 participants.
The verdict
NCT00910247, a Phase 3 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 274 participants
- Enrollment target
Study Summary
This is a long term, open-label, safety extension study in subjects with partial onset seizures.
Interventions
- DRUG Eslicarbazepine acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 274 participants |
| Start Date | 2009-08 |
| Est. Completion | 2017-04-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00910247
The ClinicalTrials.gov registry entry for NCT00910247 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 274 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Eslicarbazepine acetate is the first listed.
NCT00910247 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00910247 about?
NCT00910247 is a clinical study titled "Eslicarbazepine Acetate Monotherapy Long Term Study". This is a long term, open-label, safety extension study in subjects with partial onset seizures.
What is the current status of trial NCT00910247?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 274 participants. The study started on 2009-08. Estimated completion is 2017-04-15.
What interventions are being tested in trial NCT00910247?
The interventions under investigation include: Eslicarbazepine acetate (DRUG).
Who is sponsoring clinical trial NCT00910247?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.